Phibro Animal Health Corporation (PAHC) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $59.02. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PAHC = $216.72 (+267.2% from the current price, the stock appears undervalued). Analyst consensus target is PAHC = $49 (-17% upside).
Valuation: PAHC trades at a trailing Price-to-Earnings (P/E) of 25.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.28.
Financials: revenue is $1.3B, +11.7%/yr average growth. Net income is $48M, growing at +590.5%/yr. Net profit margin is 3.7% (thin). Gross margin is 30.9% (+0.6 pp trend).
Balance sheet: total debt is $762M against $286M equity (Debt-to-Equity (D/E) ratio 2.67, leveraged). Current ratio is 2.76 (strong liquidity). Debt-to-assets is 56%. Total assets: $1.4B.
Analyst outlook: 6 / 13 analysts rate PAHC as buy (46%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 49/100 (Partial), Growth 90/100 (Pass), Past 100/100 (Pass), Health 50/100 (Partial), Moat 56/100 (Partial), Future 16/100 (Fail), Income 30/100 (Fail).
